文献速递造血干细胞移植与细胞治疗白血病MDS 与骨髓增殖性肿瘤

211At-CD45放射免疫治疗联合非清髓预处理造血细胞移植的首例人体研究

First-In-Human Study of 211At-CD45 Radioimmunotherapy With Nonmyeloablative Conditioning Hematopoietic Cell Transplantation for Adults With Hematologic Malignancies.
PubMed 文献 · J Clin Oncol · 2026-10-15

该首例人体两阶段剂量探索研究在45例高危髓系恶性肿瘤或急性白血病成人中,于氟达拉滨/2-3 Gy全身照射非清髓预处理及HLA相合或单等位基因不合供者移植前,单次输注211At标记抗CD45单抗。500 μCi/kg被确定为方案规定的最大耐受剂量,肝脏毒性为剂量限制因素;1年无复发生存率42%,总生存率49%。

要点

  • 500 μCi/kg为方案规定的最大耐受剂量,肝脏毒性(VOD/SOS)为剂量限制因素。
  • 211At-CD45 RIT未延迟造血恢复、未损害供者嵌合、未增加GVHD发生率。
  • 13例基线有循环原始细胞者中12例在预处理前原始细胞清除,显示即刻细胞毒活性。

核心结论

  • 211At-CD45 RIT可整合入非清髓预处理,肝脏毒性界定其活性上限,抗肿瘤疗效证据支持II期评估。

研究设计与样本

  • 首例人体、两阶段剂量探索研究,共45例38-74岁高危髓系恶性肿瘤或急性白血病成人。
  • 移植前予单次211At标记抗CD45单抗输注,预处理为氟达拉滨/2-3 Gy全身照射,供者来自HLA相合或单等位基因不合。

主要发现

  • 接受591 μCi/kg者发生VOD/SOS,据此确定500 μCi/kg为方案规定的最大耐受剂量。
  • 输注反应轻微。
  • II期6例发生VOD/SOS,均在接受西罗莫司作为GVHD预防的无关供者移植中。
  • 13例基线有循环原始细胞者中12例在氟达拉滨/全身照射开始前原始细胞清除。
  • 估计1年无复发生存率为42%(95% CI,28%-56%),总生存率为49%(34%-62%)。

关键数值与推荐

  • 方案规定的最大耐受剂量为500 μCi/kg。
  • I期剂量范围为85-591 μCi/kg。
  • 1年无复发生存率42%(95% CI,28%-56%),1年总生存率49%(34%-62%)。

临床怎么用

  • 在高危髓系恶性肿瘤或急性白血病成人非清髓移植前可考虑211At-CD45 RIT,但需关注肝脏毒性。
  • 使用无关供者移植并以西罗莫司预防GVHD时,VOD/SOS风险需重点监测。

局限性

  • 为首例人体两阶段剂量探索研究,样本量有限(45例)。
  • II期VOD/SOS集中于接受西罗莫司预防的无关供者移植者,需进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Relapse is the dominant cause of failure after allogeneic hematopoietic cell transplantation (HCT) for aggressive hematologic malignancies. CD45-directed radioimmunotherapy (RIT) has been investigated to intensify conditioning and augment antitumor efficacy. After gaining clinical experience with β-emitting radionuclides, attention is now shifting toward α-emitters, such as astatine-211 (211At), for their more potent and precise radiation delivery with minimized toxicity to surrounding tissues. PATIENTS AND METHODS: To our knowledge, in this first-in-human, two-stage dose-finding study, we administered a single infusion of 211At-labeled anti-CD45 monoclonal antibody before nonmyeloablative conditioning with fludarabine/2-3 Gy total body irradiation and allografting from HLA-matched or single-allele-mismatched donors in 45 adults (38-74 years of age) at a high relapse risk from myeloid malignancies or acute leukemia. RESULTS: Seventeen patients were treated in stage I with 85-591 μCi/kg of 211At. The patient receiving 591 μCi/kg developed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS), thereby establishing 500 μCi/kg as the protocol-defined maximum tolerated dose and prompting initiation of stage II at that dose in 28 patients. Infusion reactions were mild. 211At-CD45 RIT did not delay hematopoietic recovery, impair donor chimerism, or increase graft-versus-host disease (GVHD) rates. In stage II, six patients (all receiving sirolimus as part of GVHD prophylaxis for unrelated donor HCT) experienced VOD/SOS. Among the 13 patients with circulating blasts at baseline, blasts cleared in 12 before initiation of fludarabine/total body irradiation, demonstrating immediate cytotoxic activity. Estimated 1-year relapse-free and overall survival were 42% (95% CI, 28%-56%) and 49% (34%-62%), respectively. CONCLUSION: 211At-CD45 RIT can be incorporated into nonmyeloablative conditioning, with liver toxicity defining activity limits. Evidence of antitumor efficacy supports phase II evaluation.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Vo PT, Walter RB, Gooley TA, et al. First-In-Human Study of 211At-CD45 Radioimmunotherapy With Nonmyeloablative Conditioning Hematopoietic Cell Transplantation for Adults With Hematologic Malignancies. J Clin Oncol. 2026. PMID: 42879732. doi:10.1200/JCO-26-00877

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。